Abstract: A method and kit for detecting the presence of tumor cells in an animal by detecting expression of VEGF-B186, determining an increased expression of VEGF-B186, or by determining an increased expression of VEGF-B186 relative to expression of VEGF-B167. The kit comprises a receptacle adapted to receive a sample and a means for detecting expression of VEGF-B186 from the sample. Also, a method for screening for anti-tumor agents.

Abstract: Method for inhibiting tumor cell formation or tumor cell growth, the method comprising administering to a patient in need thereof an antagonist to VEGF-B. Preferably, the antagonist is an anti-VEGF-B antibody, an antisense molecule, an RNAi molecule, a molecule for forming a triplex nucleic acid molecule with a VEGF-B encoding polynucleotide. Also disclosed are pharmaceutical compositions comprising the same.

Abstract: PDGF-D, a new member of the PDGFVEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides.

Abstract: A cleaning device, cleaning tool and method for cleaning outlet ports or the like and/or outlet spouts (12) or the like in soda recovery boilers of the like the cleaning device including at least one connecting rod and at least one front tool part mounted on the connecting rod.

Abstract: VEGF-B polypeptides from the PDGF family of growth factors having the property of promoting mitosis and proliferation of vascular endothelial cells, DNA sequences encoding these polypeptides, pharmaceutical compositions containing them and antibodies which react with them. The VEGF-B polypeptides are useful in stimulating angiogenesis as well as in diagnostic applications.

Abstract: In a TDMA (Time Division Multiple Access) wireless communication system, mobile stations are sorted according to their PV (Protocol Version), and packed by an enhanced FRP (Frequency Re-Packing) function or an enhanced IDCS (Interference Driven Channel Selection) function so mixing of mobile stations with different PVs on the same carrier will be avoided as far as possible. This allows mobile station capabilities to be used with greater advantage, in situations where a protocol or other performance feature used on a carrier must be compatible with the least capable mobile station on the carrier. In a broader sense, the mobile stations can be sorted and then allocated based on any appropriate indicator of mobile station capability, for example PV, mobile station ESN (Electronic Serial Number), and so forth. In this way, a common capability of all mobiles on the same carrier, can be maximized for some or all carriers within a cell.

Abstract: The present invention provides materials and methods for VEGF-B and PDGF therapy, especially therapy directed at stem cell recruitment, proliferation, and/or differentiation.

Abstract: Angiogenesis is stimulated by introducing two replication-deficient adenovirus vectors to the endothelial cells or proximate to the endothelial cells of an organism. The first vector encodes VEGF-B167 or a fragment or conservative substitution thereof, the second vector encodes VEGF-A or VEGF-C, or fragments or conservative substitutions thereof.

Abstract: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

Abstract: PDGF-D, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: A method and kit for detecting the presence of tumor cells in an animal by detecting expression of VEGF-B186, determining an increased expression of VEGF-B186, or by determining an increased expression of VEGF-B186 relative to expression of VEGF-B167. The kit comprises a receptacle adapted to receive a sample and a means for detecting expression of VEGF-B186 from the sample. Also, a method for screening for anti-tumor agents.

Abstract: A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

Abstract: VEGF-B polypeptides from the PDGF family of growth factors having the property of promoting mitosis and proliferation of vascular endothelial cells, DNA sequences encoding these polypeptides, pharmaceutical compositions containing them and antibodies which react with them. The VEGF-B polypeptides are useful in stimulating angiogenesis as well as in diagnostic applications.

Abstract: Angiogenesis is stimulated by introducing two replication-deficient adenovirus vectors to the endothelial cells or proximate to the endothelial cells of an organism. The first vector encodes VEGF-B167 or a fragment or conservative substitution thereof, the second vector encodes VEGF-A or VEGF-C, or fragments or conservative substitutions thereof.

Abstract: Complexes of a protein selected from the group consisting of VEGF-B167, VEGF-C, VEGF-D and processed VEGF-B186 and analogs thereof and the neuropilin-1 (NP-1) receptor, the extracellular domain or a ligand-binding fragment or analogue thereof; the use of such complexes in assays for growth factor proteins having substantially the same binding affinity for a cell surface receptor as VEGF-B167, VEGF-C, VEGF-D or processed VEGF-B186 and/or in promoting or antagonizing a cellular response mediated by VEGF-B167, VEGF-C, VEGF-D and/or processed VEGF-B186; and specific binding partners, e.g. antibodies, for such complexes.

Abstract: PDGF-C, a new member of the PDGF/VEGF family of growth factors, is described, as well as nucleotide sequences, its method of production, antibodies and antagonists. Also disclosed are transfected and transformed host cells expressing same and pharmaceutical compositions, and uses thereof in medical and diagnostic applications. Proteolytic processing of PDGF-C is accomplished by a serine protease. Methods for inhibiting PDGF-C activities and for treating disease caused by PDGF-C over-activity of over-expression are also disclosed.

Abstract: PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides.

Abstract: In accordance with this invention, an RPE cell membrane associated protein which has a molecular weight of about 32 kd, as determined by SDS-PAGE, has been discovered. This protein, referred to an “p32,” forms an oligomeric protein complex with the previously characterized p63 protein, a component of the membrane receptor for RBP. A nucleic acid molecule which codes for the p32 protein has also been isolated and sequence analysis shows that the p32 protein belongs to the family of short chain alcohol dehydrogenases, and exhibits 11-cis retinol dehydrogenase activity, the enzyme which catalyzes conversion of 11-cis-retinol into 11-cis retinaldehyde.

Abstract: Complexes of a protein selected from the group consisting of VEGF-B167, VEGF-C, VEGF-D and processed VEGF-B186 and analogs thereof and the neuropilin-1 (NP-1) receptor, the extracellular domain or a ligand-binding fragment or analogue thereof; the use of such complexes in assays for growth factor proteins having substantially the same binding affinity for a cell surface receptor as VEGF-B167, VEGF-C, VEGF-D or processed VEGF-B186 and/or in promoting or antagonizing a cellular response mediated by VEGF-B167, VEGF-C, VEGF-D and/or processed VEGF-B186; and specific binding partners, e.g. antibodies, for such complexes.

Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.